Procter & Gamble CEO Shailesh Jejurikar sells $5.7M in shares

Shailesh Jejurikar, Chairman, President and CEO of Procter & Gamble Co. (NYSE:PG), sold shares of the company’s common stock on October 23, 2026, following the exercise of stock options.

Mr. Jejurikar disposed of 35,000 shares, generating a total of $5,708,048. The shares were sold at a weighted average price of $163.0871, with individual sales occurring within a price range of $163.00 to $163.20. This sale followed the acquisition of 35,000 shares upon the exercise of stock options, which were acquired at an exercise price of $78.52 per share, totaling $2,748,200. The transaction comes as Procter & Gamble, with a market capitalization of $370.7 billion, trades near its 52-week high of $167.25. According to InvestingPro data, the consumer goods giant has raised its dividend for 43 consecutive years and currently offers a dividend yield of 2.72%.

Following these transactions, Mr. Jejurikar directly holds 55,390.9973 shares of Procter & Gamble common stock. He also maintains indirect beneficial ownership of additional shares, including 3,777.6856 shares through a Retirement Plan Trustee, reflecting an adjustment through September 30, 2026. Furthermore, 19,757 shares are held via the Sankhya S Jejurikar Revocable Trust, and 35,836 shares are held via the Shailesh Jejurikar Trust. For investors seeking deeper insights into PG’s valuation, InvestingPro analysis suggests the stock is slightly undervalued based on its Fair Value assessment. The platform offers a comprehensive Pro Research Report on PG, one of 1,400+ US equities covered, along with 10 additional ProTips to help investors make informed decisions.

In terms of derivative securities, Mr. Jejurikar retains 70,170 stock options directly following the reported exercise. These options have an exercise price of $78.52 and are exercisable from February 28, 2021, with an expiration date of February 28, 2028.

In other recent news, Procter & Gamble reported fiscal first-quarter results that exceeded Wall Street expectations, with core earnings of $2.00 per share and revenue of $23.28 billion. These figures surpassed analyst estimates of $1.89 per share and $22.82 billion in revenue, driven by robust organic growth across all product categories. Despite higher raw material and freight costs impacting margins, the company demonstrated strong performance.

Morgan Stanley raised its price target for Procter & Gamble to $185 from $166, maintaining an Overweight rating, citing the company’s strong first-quarter results and better-than-expected organic sales growth of 4.0%. TD Cowen also increased its price target to $166 from $150, highlighting the company’s strong first-quarter performance and its potential to meet the high end of full-year sales and earnings guidance. Piper Sandler adjusted its price target to $167 from $145, maintaining a Neutral rating, and noted the company’s top-line momentum.

These recent developments reflect Procter & Gamble’s ongoing turnaround progress and sales momentum.